One of Reva’s primary products is a stent for coronary artery disease that dissolves in the body over time. Use of the product, known as Fantom Encore, declined significantly in 2018 after new guidelines related to bioresorbable coronary scaffolds were published in Europe, the product’s only market, according to a Securities and Exchange Commission
Due to the poor performance of Fantom Encore, Reva’s revenue projections for the 2019 fiscal year ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.